85 related articles for article (PubMed ID: 872139)
1. Initial clinical study with pyrazofurin.
Ohnuma T; Holland JF
Cancer Treat Rep; 1977; 61(3):389-94. PubMed ID: 872139
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of pyrazofurin in refractory acute myelogenous leukemia.
Vogler WR; Trulock PD
Cancer Treat Rep; 1978 Oct; 62(10):1569-71. PubMed ID: 152146
[TBL] [Abstract][Full Text] [Related]
3. A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia.
Van Echo DA; Chiuten DF; Markus S; Wiernik PH
Cancer Clin Trials; 1981; 4(2):129-33. PubMed ID: 6166406
[TBL] [Abstract][Full Text] [Related]
4. Initial clinical study with vindesine: tolerance to weekly iv bolus and 24-hour infusion.
Ohnuma T; Greenspan EM; Holland JF
Cancer Treat Rep; 1980 Jan; 64(1):25-30. PubMed ID: 6929728
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
Nichols WC; Kvols LK; Ingle JN; Edmonson JH; Ahmann DL; Rubin J; O'Connell MJ
Cancer Treat Rep; 1978 May; 62(5):837-9. PubMed ID: 657166
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory acute nonlymphocytic leukemia with a combination of pyrazofurin and cytarabine.
Kaplan HG; Appelbaum FR; Cheever MA; Greenberg PD; Wood T; Fefer A
Cancer Treat Rep; 1982 Jun; 66(6):1397-8. PubMed ID: 7083242
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel administered by a 1-hour infusion: A phase I-II trial comparing two schedules.
Hainsworth JD; Raefsky EL; Greco FA
Cancer J Sci Am; 1995; 1(4):281-7. PubMed ID: 9166489
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
Machover D; Gastiaburu J; Delgado M; Goldschmidt E; Hulhoven R; Misset JL; de Vassal F; Tapiero H; Ribaud P; Schwarzenberg L
Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II study of continuous 5-day infusion mitomycin-C.
Yap HY; Valdivieso M; Blumenschein G; Hortobagyi G; Bedikian A
Am J Clin Oncol; 1983 Feb; 6(1):109-12. PubMed ID: 6404154
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of mitoxantrone by 24-hour continuous infusion.
Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial of weekly pyrazofurin.
Cummings FJ; Stoller RG; Calabresi P
Cancer Treat Rep; 1979 Aug; 63(8):1363-5. PubMed ID: 157807
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
Alberts SR; Erlichman C; Reid JM; Sloan JA; Ames MM; Richardson RL; Goldberg RM
Clin Cancer Res; 1998 Sep; 4(9):2111-7. PubMed ID: 9748127
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
Chang AY; Boros L; Asbury R; Hui L; Rubins J
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-69-S17-71. PubMed ID: 9374098
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of pyrazofurin and 5-azacytidine in refractory adult acute leukemia.
Martelo OJ; Broun GO; Petruska PJ
Cancer Treat Rep; 1981; 65(3-4):237-9. PubMed ID: 6165467
[TBL] [Abstract][Full Text] [Related]
18. Sequential combination of pyrazofurin and 5-azacytidine in patients with acute myelocytic leukemia and carcinoma.
Chahinian AP; Ohnuma T; Greenfield DS; Holland JF
Oncology; 1981; 38(1):7-12. PubMed ID: 6160442
[TBL] [Abstract][Full Text] [Related]
19. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
